Crescent Biopharma, Inc. CBIO
13.33 USD +0.27 (+2.04%)
Nov 4, 2026, 11:07 AM EST
13.17 Day range 14.01
8.72 52-week range 27.41
- YTD
- +12.36%
- 1 year
- +7.12%
- Market cap
- 493.87M
- EPS (ttm)
- -7.63
- Shares out
- 37.98M
- Forward P/E
- -17.04
- Dividend
- 15.94
- Ex-dividend date
- Jan 12, 2023
- YTD return
- +12.36%
- 1-year return
- +7.12%
- Volume
- 35.83K
- Avg volume
- 344.43K
- Open
- 13.43
- Previous close
- 13.06
- Day's range
- 13.17 – 14.01
- 52-week range
- 8.72 – 27.41
- Beta
- 1.29
- Analysts
- Hold
- Earnings date
- Oct 26, 2023
2Y -27.56 (-67.22%)
Key statistics
- Enterprise value
- 50.50M
- PEG ratio
- 0.00
- Price / book
- 0.00
- Dividend yield
- 792.92%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -3.02M
- Total cash
- 2.23M
- Total debt
- 0
- Return on equity
- -269.01%
- Short % of float
- 0.11%
- 50-day average
- 0.638078
- 200-day average
- 0.365086
Analyst view
Consensus: hold
Hold
Price target (mean) —
Ratings (0m) 3 3 buy · 0 hold · 0 sell
- Strong buy1
- Buy2
- Hold0
- Sell0
- Strong sell0
Next earnings
Oct 26, 2023
Expected Oct 26, 2023. Consensus EPS estimate -0.05.
Financials — quick view
CBIO Revenue — quarterly 0
CBIO Net income — quarterly -24.84M
CBIO EPS — quarterly -0.74
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Oct 26, 2023 | Sep 1, 2023 | -0.05 | — | — | — |
| Aug 14, 2023 | Jun 1, 2023 | -0.07 | — | — | — |
| May 15, 2023 | Mar 1, 2023 | 0.00 | — | — | — |
| Mar 30, 2023 | Dec 1, 2022 | 0.00 | — | — | — |
| Nov 14, 2022 | Sep 1, 2022 | 0.00 | — | — | — |
| Aug 15, 2022 | Jun 1, 2022 | -0.22 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 14, 2021 | Raymond James | down | Outperform | Market Perform |
| Aug 5, 2021 | Raymond James | main | — | Outperform |
| Apr 28, 2021 | Raymond James | main | — | Outperform |
| Feb 9, 2021 | Piper Sandler | init | — | Overweight |
| Feb 3, 2021 | Raymond James | main | — | Outperform |
| Jan 3, 2019 | Oppenheimer | init | — | Outperform |
About Crescent Biopharma, Inc.
Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on development and commercialization of liver fibrosis associated with a broad spectrum of chronic liver diseases in the United States and internationally. It develops Hydronidone, that has completed phase 1 clinical trial for the treatment of nonalcoholic steatohepatitis, a severe form of nonalcoholic fatty liver disease. The company was founded in 2002 and is headquartered in South San Francisco, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- catalystbiosciences.com
News
Crescent Biopharma Announces Grants of Inducement Awards 
Crescent Biopharma to Present at November Investor Conferences 
Crescent Biopharma (NASDAQ:CBIO) Stock Rating Reaffirmed as Buy by HC Wainwright 
HC Wainwright & Co. Reiterates Buy on Crescent Biopharma, Maintains $36 Price Target 
Crescent Biopharma Says Global Phase 1/2 APOLLO Trial Of CR-002, a PD-L1-Targeted ADC, On Track To Commence Dosing This Quarter; Initial Data Expected In H2 2027; Phase 1/2 Trial Of CR-003 (SKB105), An ITGB6-Targeted ADC, Ongoing In China; Initial Data Expected In Q1 2027 
Crescent Biopharma Announces Clinical Pipeline Momentum, including Enrolling Patients in Standard of Care Chemotherapy Combination Cohorts of Global Phase 1/2 ASCEND Trial of CR-001, a PD-1 x VEGF Bispecific Antibody, and Initiation of Additional ADC Combination Studies with CR-001 
Crescent Biopharma Announces Grants of Inducement Awards 
HC Wainwright & Co. Upgrades Crescent Biopharma to Buy, Announces $36 Price Target 
Crescent Biopharma Receives FDA Clearance For Its Investigational New Drug Application For CR-002 To Treat Advanced Solid Tumors 
Crescent Biopharma Announces FDA Clearance of IND Application for CR-002, a PD-L1-targeted Topoisomerase Inhibitor ADC, for the Treatment of Solid Tumors
Your note
Sign in to keep a note on CBIO — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| HUNT ANDREA | Director | Stock Award(Grant) | Jan 6, 2022 | 28,228 |
| LING GEOFFREY M. D. | Director | Stock Award(Grant) | Jan 6, 2022 | 31,790 |
| WILLIAMS EDDIE | Director | Stock Award(Grant) | Jan 6, 2022 | 34,804 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Renaissance Technologies, LLC | 2.04% | 774,386 | 272.27K | Jun 29, 2023 |
| Geode Capital Management, LLC | 0.71% | 270,033 | 94.94K | Jun 29, 2023 |
| Blackrock Inc. | 0.40% | 153,657 | 54.02K | Jun 29, 2023 |
| Acadian Asset Management. LLC | 0.38% | 144,028 | 50.64K | Jun 29, 2023 |
| Kynam Capital Management, LP | 0.24% | 89,886 | 31.60K | Jun 29, 2023 |
| Northern Trust Corporation | 0.23% | 86,412 | 30.38K | Jun 29, 2023 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Extended Market Index Fund | 0.42% | 160,399 | 35.29K | May 30, 2023 |
| Fidelity Series Total Market Index Fund | 0.09% | 34,507 | 7.59K | May 30, 2023 |
| Fidelity Total Market Index Fund | 0.09% | 35,667 | 7.85K | May 30, 2023 |
| Fidelity NASDAQ Composite Index Fund | 0.07% | 25,124 | 5.53K | May 30, 2023 |
| iShares Core S&P Total U.S. Stock Market ETF | 0.02% | 7,752 | 4.34K | Aug 30, 2023 |